Fluoroquinolones for the treatment of outpatient community-acquired pneumonia

Diagnostic Microbiology and Infectious Disease

Volumn 44, Issue 1, 2002, Pages 69-76

  Jones, Ronald N ^a,b   Mandell, Lionel A ^c  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CINOXACIN; CIPROFLOXACIN; ENOXACIN; GATIFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MACROLIDE; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; OXOLINIC ACID; PIPEMIDIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN;

ABDOMINAL PAIN; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BIOAVAILABILITY; COMMUNITY; DIARRHEA; DRUG ACTIVITY; DRUG TOLERANCE; HEADACHE; HOSPITAL; HUMAN; OUTPATIENT; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; VERTIGO; VOMITING;

ADULT; AGE FACTORS; AGED; AMBULATORY CARE; ANTI-INFECTIVE AGENTS; CANADA; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; FLUOROQUINOLONES; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PNEUMONIA, BACTERIAL; RISK ASSESSMENT; SAFETY; TREATMENT OUTCOME;

EID: 0036746021     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(02)00445-5     Document Type: Article

References (70)

1. Adelglass J., DeAbate C.A., McElvaine P., Fowler C.L., LoCocco J., Campbell T. Comparison of the effectiveness of levofloxacin and amoxicillin-clavulanate for the treatment of acute sinusitis in adults. Otolaryngol Head Neck Surg. 120:1999;320-327.
2. Adelglass J, Jones T.M., Ruoff G., Kahn J.B., Wiesinger B.A., Rielly-Gauvin K., Siu C.O. A multicenter, investigator-blinded, randomized comparison of oral levofloxacin and oral clarithromycin in the treatment of acute bacterial sinusitis. Pharmacotherapy. 18:1998;1255-1263.
3. Allegra L., Konietzko N., Leophonte P., Hosie J., Pauwels R., Guyen J.N., Petitpretz P. Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary diseaseA double-blind, randomised, parallel, multicentre study. J Antimicrob Chemother. 37:(Suppl A):1996;93-104.
4. Ambrose P.G., Owens R.C. Jr. New antibiotics in pulmonary and critical care medicineFocus on advanced generation quinolones and cephalosporins. Semin Respir Crit Care Med. 21:2002;19-32.
5. Aminimanizani A., Beringer P., Jelliffe R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin Pharmacokinet. 40:2001;169-187.
6. Anonymous. Fluoroquinolones exhibit differences in their incidence of rare adverse effects. Drugs Ther Perspect. 7:1996;10-13.
7. Aubier M., Verster R., Regamey C., Geslin P., Vercken J.B. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Sparfloxacin European Study Group Clin Infect Dis. 26:1998;1312-1320.
8. Ball P. The quinolonesHistory and overview. Andriole V., The Quinolones. 2000;1-31 Academic Press, New York.
9. Ball P. Future of the quinolones. Semin Respir Infect. 16:2001;215-224.
10. Ball P., Tillotson G. Tolerability of fluoroquinolone antibiotics. Past, present and future. Drug Saf. 13:1995;343-358.
11. Bartlett J.G., Dowell S.F., Mandell L.A., File T.M. Jr, Musher D.M., Fine M.J. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 31:2000;347-382.
12. Bauer T., Santiago E., Marcos M.A., Schultze-Werninghaus G., Torres A. Streptococcus pneumoniae in community-acquired pneumonia. How important is drug resistance? Med Clin North Am. 85:2001;1367-1379.
13. Bébéar C.M., Renaudin H., Charron A., Bové J.M., Bebear C., Renaudin J. Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro. Antimicrob Agents Chemother. 42:1998;2304-2311.
14. Bertino J. Jr, Fish D. The safety profile of the fluoroquinolones. Clin Ther. 22:2000;798-817.
15. Blum M.D., Graham D.J., McCloskey C.A. Temafloxacin syndromeReview of 95 cases. Clin Infect Dis. 18:1994;946-950.
16. Breen J., Skuba K., Grasela D. Safety and tolerability of gatifloxacin, an advanced-generation, 8-methoxy fluoroquinolone. J Respir Dis. 20:(Suppl):1999;S70-S76.
17. Burke T., Villanueva C., Mariano H. Jr, Huck W., Orchard D., Haverstock D., Heyd A., Church D., Sinusitis Infection Study Group . Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Clin Ther. 21:1999;1664-1677.
18. Chodosh S., DeAbate C.A., Haverstock D., Aneiro L., Church D., Bronchitis Study Group . Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. Respir Med. 94:2000;18-27.
19. Davidson R., Cavalcanti R., Brunton J.L., Bast D.J., de Azavedo J.C.S., Kibsey P., Fleming C., Low D.E. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med. 346:2002;747-750.
20. DeAbate C.A., Henry D., Bensch G., Jubran A., Chodosh S., Harper L., Tipping D., Talbot G.H., Sparfloxacin Multicenter ABECB Study Group . Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitisA multicenter, double-blind, randomized, comparative study. Chest. 114:1998;120-130.
21. Domagala J.M. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother. 33:1994;685-706.
22. Drlica K., Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 61:1997;377-392.
23. Empey P.E., Jennings H.R., Thornton A.C., Rapp R.P., Evans M.E. Levofloxacin failure in a patient with pneumococcal pneumonia. Ann Pharmacother. 35:2001;687-690.
24. Fein A.M. Pneumonia in the elderlyOverview of diagnostic and therapeutic approaches. Clin Infect Dis. 28:1999;726-729.
25. Feldman C. Pneumonia in the elderly. Clin Chest Med. 20:1999;563-573.
26. File T.M. Jr, Segreti J., Dunbar L., Player R., Kohler R., Williams R.R., Kojak C., Rubin A. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother. 41:1997;1965-1972.
27. File T.M., Tan J.S. Incidence, etiologic pathogens, and diagnostic testing of community-acquired pneumonia. Curr Opin Pulm Med. 3:1997;89-97.
28. Fish D.N. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy. 21:(10 pt 2):2001;253S-272S.
29. Fish D.N., North D.S. Gatifloxacin, an advanced 8-methoxy fluoroquinolone. Pharmacotherapy. 21:2001;35-59.
30. Fogarty C., McAdoo M., Paster R.Z., Martel A.Y., Macko A.C., Breen J. The results of a randomized, double-blind, multicenter trialGatifloxacin vs clarithromycin in the management of acute sinusitis. J Respir Dis. 20:(Suppl):1999;S17-S22.
31. Fukuda H., Hiramatsu K. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother. 43:1999;410-412.
32. Gajjar D.A., LaCreta F.P., Uderman H.D., Kollia G.D., Duncan G., Birkhofer M.J., Grasela D.M. A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men. Pharmacotherapy. 20:2000;49S-58S.
33. Gajjar D.A., LaCreta F.P., Kollia G.D., Stolz R.R., Berger S., Smith W.B., Swingle M., Grasela D.M. Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise. Pharmacotherapy. 20:2000;76S-86S.
34. Gotfried M.H., DeAbate C.A., Fogarty C., Mathew C.P., Sokol W.N. Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis. Clin Ther. 23:2001;97-107.
35. Grasela D.M., LaCreta F.P., Kollia G.D., Randall D.M., Stoltz R.R., Berger S. Lack of effect of multiple-dose gatifloxacin on oral glucose tolerance, glucose and insulin homeostasis, and glyburide pharmacokinetics in type II, non-insulin-dependent diabetes mellitus (NIDDM). 1999;. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy:San Francisco, September26-29.
36. Heffelfinger J.D., Dowell S.F., Jorgensen J.H., Klugman K.P., Mabry L.R., Musher D.M., Plouffe J.F., Rakowsky A., Schuchat A., Whitney C.G., Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group . Management of community-acquired pneumonia in the era of pneumococcal resistance. A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med. 160:2000;1399-1408.
37. Hoban D.J., Doern G.V., Fluit A.C., Roussel-Delvallez M., Jones R.N. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 32:(Suppl 2):2001;S81-S93.
38. Hoeffken G., Meyer H.P., Winter J., Verhoef L., CAP1 Study Group . The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med. 95:2001;553-564.
39. Hooper D.C. Mechanisms of action of antimicrobialsFocus on fluoroquinolones. Clin Infect Dis. 32:(Suppl 1):2001;S9-S15.
40. Hyde T.B., Gay K., Stephens D.S., Vugia D.J., Pass M., Johnson S., Barrett N.L., Schaffner W., Cieslak P.R., Maupin P.S., Zell E.R., Jorgensen J.H., Facklam R.R., Whitney C.G., Active Bacterial Core Surveillance/Emerging Infectious Program Network . Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA. 286:2001;1857-1862.
41. Kays M.B., Wack M.E., Denys G.A. Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae. Pharmacotherapy. 3:2002;395-399.
42. King D.E., Malone R., Lilley S.H. New classification and update on the quinolone antibiotics. Am Fam Physician. 61:2000;2741-2748.
43. Lasko B., Lau C.Y., Saint-Pierre C., Reddington J.L., Martel A., Anstey R.J., Canadian Sinusitis Study Group . Efficacy and safety of oral levofloxacin compared with clarithromycin in the treatment of acute sinusitis in adultsA multicentre, double-blind, randomized study. J Int Med Res. 26:1998;281-291.
44. Lesher G.Y., Froelich E.D., Gruett M.D., Bailey J.H., Brundage R.P. Naphthyridine derivativesA new class of chemotherapeutic agents. J Med Pharm Chem. 5:1962;1063-1068.
45. Lipsky B.A., Baker C.A. Fluoroquinolone toxicity profilesA review focusing on newer agents. Clin Infect Dis. 28:1999;352-364.
46. Mandell L.A., Ball P., Tillotson G. Antimicrobial safety and tolerabilityDifferences and dilemmas. Clin Infect Dis. 32:(Suppl 1):2001;S72-S79.
47. Mandell L.A., Marrie T.J., Grossman R.F., Chow A.W., Hyland R.H., Canadian Community-Acquired Pneumonia Working Group . Canadian guidelines for the initial management of community-acquired pneumoniaAn evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis. 31:2000;383-421.
48. Moroney C., Fitzgerald M.A. Management of pneumonia in elderly people. J Am Acad Nurse Pract. 8:1996;237-241.
49. Nicolle L.E. Quinolones in the aged. Drugs. 58:(Suppl 2):1999;49-51.
50. Niederman M.S., Mandell L.A., Anzueto A., Bass J.B., Broughton W.A., Campbell G.D., Dean N., File T., Fine M.J., Gross P.A., Martinez F., Marrie T.J., Plouffe J.F., Ramirez J., Sarosi G.A., Torres A., Wilson R., Yu V.L. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 163:2001;1730-1754.
51. Norrby S.R., Lietman P.S. Safety and tolerability of fluoroquinolones. Drugs. 45:(Suppl 3):1993;59-64.
52. O'Donnell J.A., Gelone S.P. Fluoroquinolones. Infect Dis Clin North Am. 14:2000;489-513.
53. Owens R.C. Jr, Ambrose P.G. Clinical use of the fluoroquinolones. Med Clin North Am. 84:2000;1447-1469.
54. Owens R.C. Jr, Ambrose P.G. Torsades de pointes associated with fluoroquinolones. Pharmacotherapy. 22:2002;663-667.
55. Paladino J.A. Is more than one quinolone needed in clinical practice? Ann Pharmacother. 35:2001;1085-1095.
56. Petitpretz P., Arvis P., Marel M., Moita J., Urueta J., CAP5 Moxifloxacin Study Group . Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest. 119:2001;185-195.
57. Pfaller M.A., Ehrhardt A.F., Jones R.N. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the Respiratory Surveillance Program StudyMicrobiology from the medical office practice environment. Am J Med. 111:(Suppl 1):2001;4-12.
58. Rajagopalan S., Yoshikawa T.T. Antimicrobial therapy in the elderly. Med Clin North Am. 85:2001;1-14.
59. Ramirez A., Molina J., Dolmann A., Fogarty C., DeAbate C.A., Breen J. Gatifloxacin treatment in patients with acute exacerbations of chronic bronchitisClinical trial results. J Respir Dis. 20:(Suppl):1999;S30-S39.
60. Ramirez J., Unowsky J., Talbot G.H., Zhang H., Townsend L. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. Clin Ther. 21:1999;103-117.
61. Schmuck G., Schürmann A., Schlüter G. Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model. Antimicrob Agents Chemother. 42:1998;1831-1836.
62. Shalier P.A., Randinitis E., Rausch G. Effect of clinafloxacin on serum insulin and glucose levels in healthy subjects. Clin Pharmacol Ther. 61:1997;148.
63. Stalam M., Kaye D. Antibiotic agents in the elderly. Infect Dis Clin North Am. 14:2000;357-369.
64. Sullivan J.G., McElroy A.D., Honsinger R.W., McAdoo M., Harrison B.J., Plouffe J.F., Gotfried M., Mayer H. Treating community-acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin. J Respir Dis. 20:(Suppl):1999;S49-S59.
65. Suto M.J., Domagala J.M., Roland G.E., Mailloux G.B., Cohen M.A. FluoroquinolonesRelationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity. J Med Chem. 35:1992;4745-4750.
66. Urban C., Rahman N., Zhao X., Mariano N., Segal-Maurer S., Drlica K., Rahal J.J. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J Infect Dis. 184:2001;794-798.
67. Vial T., Biour M., Descotes J., Trepo C. Antibiotic-associated hepatitisUpdate from 1990. Ann Pharmacother. 31:1997;204-220.
68. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Lexau C., Reingold A., Lefkowitz L., Cieslak P.R., Cetron M., Zell Z.R., Stat M., Jorgensen J.H., Schuchat A., for the Active Bacterial Core Surveillance. Program of the Emerging Infections Program Network . Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med. 343:2000;1917-1924.
69. Wilson R., Kubin R., Ballin I., Deppermann K.-M., Bassaris H.P., Leophonte P., Schreurs A.J.M., Torres A., Sommerauer B. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 44:1999;501-513.
70. Wise R., Honeybourne D. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract. Eur Respir J. 14:1999;221-229.